"The
overwhelming support our stockholders have expressed for this
combination reflects the compelling value and important opportunity to
shape the future of healthcare we see with Siemens Healthineers," said
Dow Wilson, Chief Executive Officer. "This vote brings us closer not
only toward completing this transformative combination, but also toward
realizing our vision of a world without fear of cancer. We look forward
to securing the remaining regulatory approvals and closing the
transaction."
Varian
continues to work toward completing the transaction and remains focused
on supporting customers and their patients. The transaction is expected
to close in the first half of calendar year 2021, subject to other
regulatory approvals and customary closing conditions.
The final vote results will be filed in a Form 8-K with the U.S. Securities and Exchange Commission.
About Varian
At
Varian, we envision a world without fear of cancer. For more than 70
years, we have developed, built and delivered innovative cancer care
technologies and solutions for our clinical partners around the globe to
help them treat millions of patients each year. With an Intelligent
Cancer Care approach, we are harnessing advanced technologies like
artificial intelligence, machine learning and data analytics to enhance
cancer treatment and expand access to care. Our 10,000 employees across
70 locations keep the patient and our clinical partners at the center of
our thinking as we power new victories in cancer care. Because, for
cancer patients everywhere, their fight is our fight. For more
information, visit http://www.varian.com and follow @VarianMedSys on Twitter.
